Hancock, D B
Guo, Y
Reginsson, G W
Gaddis, N C
Lutz, S M
Sherva, R
Loukola, A
Minica, C C
Markunas, C A
Han, Y
Young, K A
Gudbjartsson, D F
Gu, F
McNeil, D W
Qaiser, B
Glasheen, C
Olson, S
Landi, M T
Madden, P A F
Farrer, L A
Vink, J
Saccone, N L
Neale, M C
Kranzler, H R
McKay, J
Hung, R J
Amos, C I
Marazita, M L
Boomsma, D I
Baker, T B
Gelernter, J
Kaprio, J
Caporaso, N E
Thorgeirsson, T E
Hokanson, J E
Bierut, L J
Stefansson, K
Johnson, E O
Article History
Received: 28 March 2017
Revised: 14 July 2017
Accepted: 17 July 2017
First Online: 3 October 2017
Conflict of Interest
: Dr Bierut and the spouse of Dr Saccone are listed as inventors on U.S. Patent 8,080,371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis and treatment of addiction. Authors listed with the affiliation deCODE Genetics/AMGEN are employees of deCODE genetics/AMGEN. Although unrelated to this research, Dr Kranzler has been a consultant or advisory board member for Lundbeck and Indivior and is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor and Amygdala Neurosciences. Dr Kaprio has consulted for Pfizer in 2012–2014 on nicotine dependence. The remaining authors declare no conflict of interest.